Smart Money Group LLC Buys New Position in Novartis AG (NVS)

Smart Money Group LLC bought a new stake in Novartis AG (NYSE:NVS) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 2,818 shares of the company’s stock, valued at approximately $237,000.

Other hedge funds also recently bought and sold shares of the company. Wealthcare Advisory Partners LLC bought a new stake in shares of Novartis during the third quarter valued at about $106,000. Pinnacle Wealth Planning Services Inc. bought a new stake in shares of Novartis during the fourth quarter valued at about $113,000. Calton & Associates Inc. bought a new stake in shares of Novartis during the fourth quarter valued at about $118,000. SeaCrest Wealth Management LLC bought a new stake in shares of Novartis during the fourth quarter valued at about $124,000. Finally, Trustcore Financial Services LLC bought a new stake in shares of Novartis during the fourth quarter valued at about $178,000. Institutional investors own 10.76% of the company’s stock.

How to Become a New Pot Stock Millionaire

Shares of Novartis AG (NYSE:NVS) opened at $80.62 on Tuesday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.21 and a quick ratio of 0.91. Novartis AG has a 1 year low of $72.67 and a 1 year high of $94.19. The company has a market cap of $190,170.44, a PE ratio of 24.99, a price-to-earnings-growth ratio of 1.91 and a beta of 0.78.

Novartis (NYSE:NVS) last issued its quarterly earnings results on Wednesday, January 24th. The company reported $1.20 EPS for the quarter, topping the consensus estimate of $1.16 by $0.04. Novartis had a net margin of 15.69% and a return on equity of 16.03%. The firm had revenue of $12.92 billion for the quarter, compared to analysts’ expectations of $12.65 billion. During the same period in the previous year, the business earned $1.14 earnings per share. Novartis’s revenue for the quarter was up 4.8% compared to the same quarter last year. equities analysts anticipate that Novartis AG will post 5.36 EPS for the current year.

A number of equities research analysts recently weighed in on NVS shares. Zacks Investment Research cut shares of Novartis from a “hold” rating to a “sell” rating in a research note on Tuesday, January 2nd. Bank of America cut shares of Novartis from a “neutral” rating to an “underperform” rating in a research note on Wednesday, December 6th. UBS restated a “neutral” rating on shares of Novartis in a research note on Monday, January 15th. Nord/LB restated a “neutral” rating on shares of Novartis in a research note on Wednesday, December 27th. Finally, JPMorgan Chase & Co. restated a “neutral” rating on shares of Novartis in a research note on Thursday, January 18th. Four research analysts have rated the stock with a sell rating, eight have given a hold rating and one has issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $87.51.

TRADEMARK VIOLATION NOTICE: “Smart Money Group LLC Buys New Position in Novartis AG (NVS)” was reported by Stock Observer and is the property of of Stock Observer. If you are reading this report on another website, it was copied illegally and reposted in violation of US and international copyright legislation. The correct version of this report can be accessed at https://www.thestockobserver.com/2018/03/20/smart-money-group-llc-buys-new-position-in-novartis-ag-nvs.html.

About Novartis

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply